panCELLa’s intent to develop therapeutic products in the mesenchymal stem cell (MSC) and pancreatic islet space has recently led to the creation of Implant Therapeutics. Implant Therapeutics, under the guidance of D...
New iPSC Master Cell Banks to Accelerate Development of Novel Cell Therapies panCELLa and CCRM collaborate to benefit academia and industry April 21, 2020, (Toronto, ON) -- Toronto-based panCELLa and CCRM have exec...
panCELLa is pleased to announce that it will receive advisory services and up to $400,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to help further research and develo...
panCELLa is pleased to announce that it has extended an exclusive license to Astellas for its proprietary cell technology addressing long-term allogeneic cell tolerance without the need for immune suppression of patients...
EVOTEC LICENSES PANCELLA’S STATE-OF-THE-ART IPSC TECHNOLOGies iACT STEALTH CELL™ AND FAILSAFE™ FOR USE IN CELL THERAPY ACCESS TO PANCELLA’S TECHNOLOGY HAS THE POTENTIAL TO ENABLE SAFE AND OFF-THE-SHELF CELL TH...
Cartherics Pty Ltd ("Cartherics") and panCELLa Inc. ("panCELLa") are pleased to announce their collaboration to research, develop and commercialize products for the treatment of cancer and other debilitating diseases usi...
panCELLa is proud to announce the publication of “Linking a cell division and a suicide gene to define and improve cell therapy safety” in the November 21st 2018 issue of Nature. Available online, you may view...
With the support of Chiefswood, panCELLa brings our exclusive FailSafe System to the market. panCELLa offers a solution to the safety risks generally associated with cell therapies. The exclusive "FailSafe Cell Syst...